Volume 29, Number 3—March 2023
Synopsis
Yellow Fever Vaccine–Associated Viscerotropic Disease among Siblings, São Paulo State, Brazil
Table
Case information |
Cluster 1 |
Cluster 2 |
||||
Case 1 |
Case 2 |
Case 3 |
Case 4 |
Case 5 |
||
Patient age, y/sex | 40/M | 35/M | 28/F | 32/M | 29/M | |
Patient race |
White |
White |
White |
White |
White |
|
Kind of YF vaccine |
Standard |
Standard |
Fractionated |
Fractionated |
Fractionated |
|
Days from vaccination to symptom onset |
3 |
4 |
4 |
1 |
4 |
|
Symptoms |
Fever, headache, vomiting, abdominal pain, jaundice, bleeding |
Fever, myalgia, vomiting, diarrhea, jaundice, seizures |
Fever, myalgia, abdominal pain, dysuria, vomiting, bleeding |
Fever, myalgia, abdominal pain, jaundice, bleeding |
Fever, vomiting, myalgia, headache |
|
Platelets, per μL† | 38,000 | 29,000 | 23,000 | 29,000 | 75,000 | |
Aspartate transaminase, U/L† | 366 | 2,254 | 769 | 1,930 | 137 | |
Alanine aminotransferase, U/L | 166 | 617 | 180 | 503 | 122 | |
International normalized ratio† | 1.94 | 1.8 | 1.9 | 2.0 | 2.0 | |
Total bilirubin, mg/dL† | 8.5 | 8.5 | 6.5 | 7.6 | 0.6 | |
Creatinine, mg/dL† | 6.7 | 5.9 | 2.9 | 5.9 | 1.4 | |
Creatinine phosphokinase† |
428 |
1,061 |
13,080 |
2,770 |
514 |
|
Outcome |
Died |
Died |
Died |
Died |
Recovered |
|
RT-PCR for YF vaccine in blood | Positive, 9 DAV | Positive, 10 DAV | Positive, 11 DAV | Positive, 10 DAV | Positive, 14 DAV | |
Viral isolation in serum sample >7 DAV | Positive, 9 DAV | ND | ND | ND | ND | |
YF IgM | Detected, 9 DAV | ND | ND | Detected, 10 DAV | Negative, 14 DAV | |
Liver histopathological pattern at autopsy | Typical‡ | ND | ND | Typical‡ | ND | |
YF immunohistochemistry in hepatic tissue | Positive | NA | NA | Positive | NA | |
RT-PCR for YF in liver | ND | ND | ND | Positive | ND |
*DAV, days after vaccination; NA, not applicable; ND, not done; RT-PCR, reverse transcription PCR; YF, yellow fever. †Most altered result. ‡The liver exhibited discrete microvesicular fatty change and mixed sinusoidal inflammatory infiltrate, with no evidence of hepatocellular necrosis in the sample.
Page created: January 04, 2023
Page updated: February 19, 2023
Page reviewed: February 19, 2023
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.